Food and Drug Administration
Office of Special Nutritionals (HFS-450)
Center for Food Safety and Applied Nutrition
2800 C. Street, S W
Washington, DC 20204

Turin, 27th July 2001

## Registered letter

Dear Sirs,

Notice is hereby given pursuant to the requirements of Section 403 (r) (6) (21 U.S.C.§343 (r) (6)) of the Federal Food, Drug, and Cosmetic Act and in accordance with the requirements of 21 CFR §101.93, that Medestea Internazionale S.r.l., located in Turin, Via Magenta 43, Italy intends to market a dietary supplement CELLULASE® Gold.

Cellulase Gold contains the following ingredients: Lipovascolen ™, [Grape seed extract (vitis vinifera), Bladderwrack extract, Centella asiatica extract (leaves), Ginkgo Biloba extract (leaves), Sweet clover (Melilotus officinalis) extract (flowering tops), Ruscus aculeatus extract (rhizome)]; cysteine; RECAPTA™ [Fish oil, Borage oil (seeds), DHA Gold®, Vitamin E, Lipoic Acid, orange essential oil, thyme essential oil, Policosanols, Vitamin B6, Piper nigrum dried extract, Folic acid].

It bears the following statement(s) on the label and/or in the labelling:

- ...Helps reduce cellulite...
- ...Helps prevent cellulite...
- Deal with cellulite at its source...
- ... Works below the surface of your skin where cellulite begins.
- ... Scientifically formulated to help reduce cellulite.
- ... Works over time at the source of the problem to reduce cellulite.
- ...Increase blood circulation, reduce fluid build up, stimulate metabolism and reduce localised fat.
- ... Antioxidant, free radical scavengers.
- ...Naturally increases cell membrane fluidity.
- ... Helps keep your cells and body younger.

375 0162 LET 8449

## Sant'ANGELICA'

The undersigned certifies that the information contained in this notice is complete and accurate and that Medestea Internazionale s.r.l. has substantiation that the statement is truthful and not misleading. Pursuant to § 101.93 (a) (1) two copies of this notification are enclosed.

Sincerely,

Cinzia Pranzoni, Ph.D.

Senior Product Development Scientist

Antonio Soleti, Ph.D.

Senio Clinical Trials co-ordinator

Direct phone line: 011-39-011-51.56.629 Direct fax line: 011-39-011-562.31.43

E mail: antonio.soleti@medestea.it